North America Branded Generics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Therapeutic Application, Distribution Channel, Drug Class, and Formulation Type

List of Tables

The branded generics market in North America is expected to grow from US$ 73.15 billion in 2022 to US$ 126.24 billion by 2028; it is estimated to grow at a CAGR of 9.5% from 2022 to 2028.

The increasing penetration of branded generics drives the growth of the North America branded generics market. According to a report by VOXEU, with healthcare budgets under pressure, switching to branded generics seems a natural cost saver. Branded generics are cheaper alternatives to branded medicines. Additionally, as per the data of FDA, more than 90% of the prescription in US were filled by generic drugs during year 2020. Further, according to the Association of the Accessible Medicine, in year 2020, the generic and biosimilar drugs saved US$ 338 billion in US. Moreover, healthcare expenditure grew by 9.7% during the same year in US and reached US$ 4.1 trillion. Further, a savings of US$ 2.2 trillion is observed in healthcare expenditure during the last decade in US due to the availability of low-cost generics.

Further, the Association for Accessible Medicines report states that nearly 4 billion generic prescriptions were dispensed in 2018. According to the HSRII report, the US is the largest pharmaceutical market in the world (US$ 325 billion), accounting for one-third of the overall pharmaceutical market, with generics accounting for 84% in terms of volume of sales and 28% in terms of sales value. Furthermore, branded generics utilization has increased among the population due to savings provided low cost alternatives and by the healthcare reimbursement system. On average, in 2019, the use of generic medicines saved US$ 93 billion in Medicare savings and US$ 48.5 billion in savings to Medicaid. Hence, the rising penetration of generics stimulates the growth of the overall branded generics market.

By introducing new features and technologies, vendors in the North America branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.

North America Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)

North America Branded Generics Market Segmentation

The North America branded generics market is segmented on the basis of therapeutic application, distribution channel, drug class, formulation type, and country. Based on therapeutic application, the market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment holds the largest share of the market. The market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment holds the largest share of the market in 2022. The North America branded generics market, based on drug class, is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment holds the largest share of the market in 2022. The market, based on formulation type, is segmented into oral, parenteral, topical, and other. In 2022, the oral segment holds the largest share of the market. Based on country, the North America branded generics market is segmented into the US, Canada, and Mexico. The US holds the largest market share in 2022.

Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, MYLAN N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and TEVA PHARMACEUTICAL INDUSTRIES LTD. are among the leading companies in the branded generics market operating in this region.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America branded generics market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America branded generics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the branded generics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: BMIRE00026327

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Branded Generics Market - By Therapeutic Application
- 1.3.2 North America Branded Generics Market - By Distribution Channel
- 1.3.3 North America Branded Generics Market - By Drug Class
- 1.3.4 North America Branded Generics Market - By Formulation Type
- 1.3.5 North America Branded Generics Market - By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Branded Generics Market - Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion

5. North America Branded Generics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Penetration of Branded Generics
- 5.1.2 Surging Government Initiatives for Promoting Branded Generics
5.2 Market Restraints
- 5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
5.3 Market Opportunities
- 5.3.1 Product Differentiation Creating Opportunities
5.4 Future Trends
- 5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals
5.5 Impact Analysis

6. Branded Generics Market- North America Analysis

6.1 North America Branded Generics Market Revenue Forecast and Analysis
6.2 North America Branded Generics Market, By Country - Forecast and Analysis

7. North America Branded Generics Market Revenue and Forecast To 2028- by Therapeutic Application

7.1 Overview
7.2 North America Branded Generics Market Revenue Share, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
7.4 Cardiovascular Diseases
- 7.4.1 Overview
- 7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.5 Diabetes
- 7.5.1 Overview
- 7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
7.6 Neurology
- 7.6.1 Overview
- 7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
7.7 Gastrointestinal Diseases
- 7.7.1 Overview
- 7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.8 Dermatology Diseases
- 7.8.1 Overview
- 7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.9 Analgesics and Anti-Inflammatory
- 7.9.1 Overview
- 7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

8. North America Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel

8.1 North America Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
8.2 Hospital Pharmacies
- 8.2.1 Overview
- 8.2.2 Hospital Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.3 Retail Pharmacies
- 8.3.1 Overview
- 8.3.2 Retail Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.4 Online Pharmacies
- 8.4.1 Overview
- 8.4.2 Online Pharmacies: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
8.5 Drug Stores
- 8.5.1 Overview
- 8.5.2 Drug Stores: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)

9. North America Branded Generics Market Analysis and Forecast to 2028 by Drug Class

9.1 North America Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
9.2 Alkylating Agents
- 9.2.1 Overview
- 9.2.2 Alkylating Agents: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.3 Antimetabolites
- 9.3.1 Overview
- 9.3.2 Antimetabolites: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.4 Hormones
- 9.4.1 Overview
- 9.4.2 Hormones: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.5 Anti-hypertensive
- 9.5.1 Overview
- 9.5.2 Anti-hypertensive: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.6 Lipid Lowering Drugs
- 9.6.1 Overview
- 9.6.2 Lipid Lowering Drugs: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.7 Anti-Depressants
- 9.7.1 Overview
- 9.7.2 Anti-Depressants: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.8 Anti-psychotics
- 9.8.1 Overview
- 9.8.2 Anti-psychotics: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.9 Anti-epileptic
- 9.9.1 Overview
- 9.9.2 Anti-epileptic: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
9.10 Others
- 9.10.1 Overview
- 9.10.2 Others: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)

10. North America Branded Generics Market Analysis and Forecast to 2028 - by Formulation Type

10.1 Overview
10.2 North America Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
10.3 Oral
- 10.3.1 Overview
- 10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
10.4 Parenteral
- 10.4.1 Overview
- 10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
10.5 Topical
- 10.5.1 Overview
- 10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
10.6 Others
- 10.6.1 Overview
- 10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

11. North America Branded Generics Market Revenue and Forecasts to 2028 Country Analysis

11.1 Overview
- 11.1.1 North America: Branded Generics Market, by Country, 2022 & 2028 (%)
  - 11.1.1.1 US: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.1.1 Overview
    - 11.1.1.1.2 US: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.1.3 US: Branded Generics Market, by Therapeutic Application, 2019-2028 (US$ Billion)
    - 11.1.1.1.4 US: Branded Generics Market, by Distribution Channel, 2019-2028 (US$ Billion)
    - 11.1.1.1.5 US: Branded Generics Market, by Drug Class, 2019-2028 (US$ Billion)
    - 11.1.1.1.6 US: Branded Generics Market, by Formulation Type, 2019-2028 (US$ Billion)
  - 11.1.1.2 Canada: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.2.1 Overview
    - 11.1.1.2.2 Canada: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.2.3 Canada: Branded Generics Market, by Therapeutic Application, 2019-2028 (US$ Billion)
    - 11.1.1.2.4 Canada: Branded Generics Market, by Distribution Channel, 2019-2028 (US$ Billion)
    - 11.1.1.2.5 Canada: Branded Generics Market, by Drug Class, 2019-2028 (US$ Billion)
    - 11.1.1.2.6 Canada: Branded Generics Market, by Formulation Type, 2019-2028 (US$ Billion)
  - 11.1.1.3 Mexico: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.3.1 Overview
    - 11.1.1.3.2 Mexico: Branded Generics Market - Revenue and Forecast to 2028 (US$ Billion)
    - 11.1.1.3.3 Mexico: Branded Generics Market, by Therapeutic Application, 2019-2028 (US$ Billion)
    - 11.1.1.3.4 Mexico: Branded Generics Market, by Distribution Channel, 2019-2028 (US$ Billion)
    - 11.1.1.3.5 Mexico: Branded Generics Market, by Drug Class, 2019-2028 (US$ Billion)
    - 11.1.1.3.6 Mexico: Branded Generics Market, by Formulation Type, 2019-2028 (US$ Billion)

12. Branded Generics Market-Industry Landscape

12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. Company Profiles

13.1 MYLAN N.V.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bausch Health Companies Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Lupin
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Sanofi
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 ASTRAZENECA PLC.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Par Pharmaceuticals, INC
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Sandoz International GMBH
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Aspen Holdings
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Hetero
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms